{"id":"rvt-101","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RVT-101 works by binding to the tau protein, which is implicated in the progression of neurodegenerative diseases such as Alzheimer's disease. By inhibiting tau aggregation, RVT-101 aims to slow down disease progression and improve symptoms.","oneSentence":"RVT-101 is a small molecule that targets the tau protein to treat neurodegenerative diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:07.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT02910102","phase":"PHASE2","title":"Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia","status":"COMPLETED","sponsor":"Axovant Sciences Ltd.","startDate":"2016-10","conditions":"Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia","enrollment":38},{"nctId":"NCT02586909","phase":"PHASE3","title":"12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension","status":"TERMINATED","sponsor":"Axovant Sciences Ltd.","startDate":"2016-04-26","conditions":"Alzheimer's Disease","enrollment":1099},{"nctId":"NCT02669433","phase":"PHASE2","title":"Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study","status":"COMPLETED","sponsor":"Axovant Sciences Ltd.","startDate":"2016-01","conditions":"Dementia With Lewy Bodies","enrollment":484},{"nctId":"NCT02585934","phase":"PHASE3","title":"Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study","status":"COMPLETED","sponsor":"Axovant Sciences Ltd.","startDate":"2015-10","conditions":"Alzheimer's Disease","enrollment":1315},{"nctId":"NCT00708552","phase":"PHASE2","title":"Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-04","conditions":"Alzheimer's Disease","enrollment":576},{"nctId":"NCT02928445","phase":"PHASE2, PHASE3","title":"Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension","status":"TERMINATED","sponsor":"Axovant Sciences Ltd.","startDate":"2016-10","conditions":"Dementia With Lewy Bodies","enrollment":240},{"nctId":"NCT00710684","phase":"PHASE2","title":"A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-01","conditions":"Alzheimer's Disease","enrollment":682},{"nctId":"NCT00224497","phase":"PHASE2","title":"A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Alzheimer's Disease","enrollment":380},{"nctId":"NCT00348192","phase":"PHASE2","title":"SB-742457 And Donepezil In Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Alzheimer's Disease","enrollment":200},{"nctId":"NCT00551772","phase":"PHASE1","title":"A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Alzheimer's Disease","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RVT-101","genericName":"RVT-101","companyName":"Axovant Sciences Ltd.","companyId":"axovant-sciences-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RVT-101 is a small molecule that targets the tau protein to treat neurodegenerative diseases. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}